Flavopiridol sensitivity of cancer cells isolated from ascites and pleural fluids

Clinical Cancer Research

Volumn 11, Issue 9, 2005, Pages 3523-3529

  Richard, Christina ^a   Matthews, Donald ^a   Duivenvoorden, Wilhelmina ^a   Yau, Jonathan ^a   Wright, Paul S ^b   Th'ng, John P H ^a  

^a THUNDER BAY REGIONAL HEALTH SCIENCES CENTRE   (Canada)

^b SANOFI   (France)

Author keywords

[No Author keywords available]

Indexed keywords

3 (4,5 DIMETHYL 2 THIAZOLYL) 2,5 DIPHENYLTETRAZOLIUM BROMIDE; CARBOPLATIN; CISPLATIN; CYCLIN DEPENDENT KINASE INHIBITOR; DOXORUBICIN; FLAVOPIRIDOL; PACLITAXEL; RNA POLYMERASE II;

ADULT; AGED; ARTICLE; ASCITES FLUID; CANCER CELL; CANCER CELL CULTURE; CANCER PATIENT; CELL ISOLATION; CELL VIABILITY; CLINICAL ARTICLE; CROSS RESISTANCE; CRYSTALLOGRAPHY; DRUG EFFICACY; ENZYME INHIBITION; FEMALE; HUMAN; HUMAN CELL; LD 50; MALE; PLEURA FLUID; PRIORITY JOURNAL; TRANSCRIPTION REGULATION;

ANTINEOPLASTIC AGENTS; ASCITES; BLOTTING, WESTERN; CARBOPLATIN; CELL LINE, TUMOR; CELL PROLIFERATION; CISPLATIN; CYCLIN-DEPENDENT KINASES; DOSE-RESPONSE RELATIONSHIP, DRUG; DOXORUBICIN; FLAVONOIDS; HUMANS; NEOPLASMS; PACLITAXEL; PIPERIDINES; PLEURAL EFFUSION, MALIGNANT; PROTO-ONCOGENE PROTEINS C-BCL-2; TIME FACTORS; TUMOR CELLS, CULTURED;

EID: 18244365609     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-04-2507     Document Type: Article

References (24)

1. Zhai S, Senderowicz A, Sausville E, Figg W. Flavopiridol, a novel cyclin-dependent kinase inhibitor, in clinical development. Ann Pharmacother 2002;36:905-11.
2. Senderowicz AM. The cell cycle as a target for cancer therapy: basic and clinical findings with the small molecule inhibitors flavopiridol and UCN-01. Oncologist 2002;7:12-9.
3. Sausville EA. Complexities in the development of cyclin-dependent kinase inhibitor drugs. Trends Mol Med 2002;8:332-7.
4. Sausville EA. Cyclin-dependent kinase modulators studied at the NCI: pre-clinical and clinical studies. Curr Med Chem Anti-Canc Agents 2003;3:47-56.
5. Brusselbach S, Nettelbeck DM, Sedlacek HH, Muller R. Cell cycle-independent induction of apoptosis by the anti-tumor drug flavopiridol in endothelial cells. Int J Cancer 1998;77:146-52.
6. Bible KC, Kaufmann SH. Flavopiridol: a cytotoxic flavone that induces cell death in noncycling A549 human lung carcinoma cells. Cancer Res 1996;56: 4856-61.
7. Sedlacek HH. Mechanisms of action of flavopiridol. Crit Rev Oncol Hematol 2001;38:139-70.
8. Elsayed YA, Sausville EA. Selected novel anticancer treatments targeting cell signaling proteins. Oncologist 2001;6:517-37.
9. Liu G, Gandara DR, Lara PN Jr, et al. A phase II trial of flavopiridol (NSC #649890) in patients with previously untreated metastatic androgen-independent prostate cancer. Clin Cancer Res 2004;10:924-8.
10. Shapiro GI. Preclinical and clinical development of the cyclin-dependent kinase inhibitor flavopiridol. Clin Cancer Res 2004;10:4270-5S.
11. Tan AR, Yang X, Berman A, et al. Phase I trial of the cyclin-dependent kinase inhibitor flavopiridol in combination with docetaxel in patients with metastatic breast cancer. Clin Cancer Res 2004;10:5038-47.
12. MacDougall JR, Matrisian LM. Targets of extinction: identification of genes whose expression is repressed as a consequence of somatic fusion between cells representing basal and luminal mammary epithelial phenotypes. J Cell Sci 2000;113:409-23.
13. Carmichael J, Degraff WG, Gazdar AF, et al. Evaluation of a tetrazolium-based semiautomated colorimetric assay: assessment of chemosensitivity testing. Cancer Res 1987;47:936-42.
14. Derjuga A, Richard C, Crosato M, et al. Expression of p21Waf1/Cip1 and cyclin D1 is increased in butyrate-resistant HeLa cells. J Biol Chem 2001;276: 37815-20.
15. Li Y, Bhuiyan M, Alhasan S, et al. Induction of apoptosis and inhibition of c-erbB-2 in breast cancer cells by flavopiridol. Clin Cancer Res 2000;6:223-9.
16. Li Y, Chinni SR, Senderowicz AM, Sarkar FH. Induction of growth inhibition and apoptosis in prostate cancer cells by flavopiridol. Int J Oncol 2000;17: 755-9.
17. Konig A, Schwartz GK, Mohammad RM, et al. The novel cyclin-dependent kinase inhibitor flavopiridol downregulates bcl-2 and induces growth arrest and apoptosis in chronic B-cell leukemia lines. Blood 1997;90:4307-12.
18. Newcomb EW, Tamasdan C, Entzminger Y, et al. Flavopiridol induces mitochondrial-mediated apoptosis in murine glioma GL261 cells via release of cytochrome c and apoptosis inducing factor. Cell Cycle 2003;2:243-50.
19. Boerner SA, Tourne ME, Kaufmann SH, Bible KC. Effect of P-glycoprotein on flavopiridol sensitivity. Br J Cancer 2001;84:1391-6.
20. Nakanishi T, Karp JE, Tan M, et al. Quantitative analysis of breast cancer resistance protein and cellular resistance to flavopiridol in acute leukemia patients. Clin Cancer Res 2003;9:3320-8.
21. Robey RW, Medina-Perez WY, Nishiyama K, et al. Overexpression of the ATP-binding cassette half-transporter, ABCG2 (MXR/BCRP/ABCP1), in flavopiridol-resistant human breast cancer cells. Clin Cancer Res 2001;7:145-52.
22. Doyle LA, Ross DD. Multidrug resistance mediated by the breast cancer resistance protein BCRP (ABCG2). Oncogene 2003;22:7340-58.
23. Bible KC, Boerner SA, Kirkland K, et al. Characterization of an ovarian carcinoma cell line resistant to cisplatin and flavopiridol. Clin Cancer Res 2000;6: 661-70.
24. Rudek MA, Bauer KS Jr, Lush RM III, et al. Clinical pharmacology of flavopiridol following a 72-hour continuous infusion. Ann Pharmacother 2003;37:1369-74.